HDAC9 and neoplasm: Besides its role as tumour suppressor, emerging evidence suggest that lack of protein or loss-of-function mutations in FBXW7 confer resistance to antitubulin agents (Wertz et al. 2011), while sensitizing to HDAC inhibitors (Garnett et al. 2012).